98 related articles for article (PubMed ID: 4032756)
21. [Phase II study of 5'-DFUR in uterine cervical cancer and ovarian cancer].
Noda K; Ikeda M; Saito Y; Yajima A; Sato A; Suzuki M; Terashima Y; Ochiai K; Yoshida K; Takada M
Gan To Kagaku Ryoho; 1991 Dec; 18(15):2557-65. PubMed ID: 1660700
[TBL] [Abstract][Full Text] [Related]
22. [The hypoplastic state of hematopoiesis following chemotherapy with alkylating compounds].
Kholodnyi MD; Mindlin SS
Vopr Onkol; 1969; 15(8):27-32. PubMed ID: 4982329
[No Abstract] [Full Text] [Related]
23. Collateral sensitivity of 6-mercaptopurine-resistant sublines of P388 and L1210 leukemia to the new purine antagonists, 5-carbamoyl-1H-imidazol-4-yl piperonylate and 4-carbamoylimidazolium 5-olate.
Inaba M; Fukui M; Yoshida N; Tsukagoshi S; Sakurai Y
Cancer Res; 1982 Mar; 42(3):1103-6. PubMed ID: 6277474
[TBL] [Abstract][Full Text] [Related]
24. [Current results and perspectives of the use of human tumor cell lines for antitumor drug screening].
Zhukova OS; Dobrynin IaV
Vopr Onkol; 2001; 47(6):706-9. PubMed ID: 11826493
[TBL] [Abstract][Full Text] [Related]
25. Mitomycin (Mutamycin).
Med Lett Drugs Ther; 1975 Jul; 17(15):62-3. PubMed ID: 50555
[No Abstract] [Full Text] [Related]
26. Carzelesin phase II study in advanced breast, ovarian, colorectal, gastric, head and neck cancer, non-Hodgkin's lymphoma and malignant melanoma: a study of the EORTC early clinical studies group (ECSG).
Pavlidis N; Aamdal S; Awada A; Calvert H; Fumoleau P; Sorio R; Punt C; Verweij J; van Oosterom A; Morant R; Wanders J; Hanauske AR
Cancer Chemother Pharmacol; 2000; 46(2):167-71. PubMed ID: 10972487
[TBL] [Abstract][Full Text] [Related]
27. 1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) given alone and combined with antimetabolites in the treatment of advanced solid tumors.
Cohen SM; Weiner MJ; Greenspan EM
Cancer Chemother Rep; 1972 Dec; 56(6):751-4. PubMed ID: 4660631
[No Abstract] [Full Text] [Related]
28. [Phase II study of FF-705 by Clinical Cooperative Study Group].
Gan To Kagaku Ryoho; 1984 Jan; 11(1):150-6. PubMed ID: 6230055
[TBL] [Abstract][Full Text] [Related]
29. Curative cancer chemotherapy.
Frei E
Cancer Res; 1985 Dec; 45(12 Pt 1):6523-37. PubMed ID: 2998603
[TBL] [Abstract][Full Text] [Related]
30. [Phase II study of mitoxantrone].
Tada A; Ogawa M; Usui N; Inagaki J; Horikoshi N; Inoue K; Ikeda K; Adachi K; Nakada H; Okada Y
Gan To Kagaku Ryoho; 1984 Aug; 11(8):1649-54. PubMed ID: 6476838
[TBL] [Abstract][Full Text] [Related]
31. Selective reduction of intracellular guanosine 5'-triphosphate pool by 4-carbamoylimidazolium 5-olate in murine tumor cells.
Fukui M; Inaba M; Tsukagoshi S; Sakurai Y
Cancer Res; 1986 Jan; 46(1):43-6. PubMed ID: 2866032
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy in prevention of the recurrence of resectable cancer.
Bonadonna G; Tancini G; Rossi A; Gasparini M
Annu Rev Med; 1978; 29():149-75. PubMed ID: 206184
[No Abstract] [Full Text] [Related]
33. Interval between port catheter flushing can be extended to four months.
Ignatov A; Ignatov T; Taran A; Smith B; Costa SD; Bischoff J
Gynecol Obstet Invest; 2010; 70(2):91-4. PubMed ID: 20224280
[TBL] [Abstract][Full Text] [Related]
34. In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations.
Ahmann FR; Meyskens FL; Moon TE; Durie BG; Salmon SE
Cancer Res; 1982 Nov; 42(11):4495-8. PubMed ID: 6897012
[TBL] [Abstract][Full Text] [Related]
35. Clinical drug development: an analysis of phase II trials, 1970-1985.
Marsoni S; Hoth D; Simon R; Leyland-Jones B; De Rosa M; Wittes RE
Cancer Treat Rep; 1987 Jan; 71(1):71-80. PubMed ID: 3791270
[TBL] [Abstract][Full Text] [Related]
36. A study on the induction of differentiation of human leukemic cells by harringtonine combined with cytarabine.
Huang CL; Deng ML; Guo RJ; Wu MT; Liu FZ; Liang YM; Qiao QD
Leukemia; 1988 Aug; 2(8):518-22. PubMed ID: 3412024
[TBL] [Abstract][Full Text] [Related]
37. [Clinical trial of 5'-DFUR against various malignant tumors].
Okumura T
Gan To Kagaku Ryoho; 1985 Dec; 12(12):2365-70. PubMed ID: 2934025
[TBL] [Abstract][Full Text] [Related]
38. Drug management of malignant disease.
Fennelly JJ
Ir Med J; 1983 Jul; 76(7):326-31. PubMed ID: 6350216
[No Abstract] [Full Text] [Related]
39. Cisplatin resistance in human cervical, ovarian and lung cancer cells.
Chen J; Solomides C; Parekh H; Simpkins F; Simpkins H
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1217-27. PubMed ID: 25894720
[TBL] [Abstract][Full Text] [Related]
40. [Anticytogram (author's transl)].
Ciuffi M
Quad Sclavo Diagn; 1979 Jun; 15 Suppl 1():662-72. PubMed ID: 400252
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
